All‐cause mortality · adults in sinus rhythm after cardioversion of atrial fibrillation
Metoprolol showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults in sinus rhythm after cardioversion of atrial fibrillation
Metoprolol leads to higher withdrawals due to adverse effects compared with placebo or no treatment (high certainty).
1 finding from 1 review
Proarrhythmia · adults in sinus rhythm after cardioversion of atrial fibrillation
Metoprolol leads to higher proarrhythmia compared with placebo or no treatment (high certainty).
1 finding from 1 review
Stroke · adults in sinus rhythm after cardioversion of atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of atrial fibrillation · adults in sinus rhythm after cardioversion of atrial fibrillation
Metoprolol showed no clear difference in recurrence of atrial fibrillation compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
All‐cause mortality, 30 days1 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in all‐cause mortality, 30 days1 compared with placebo (low certainty).
1 finding from 1 review
All cardiovascular death · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in cardiovascular death, 30 days3 compared with placebo (low certainty).
2 findings from 1 review
AAA‐related death, 30 days4 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in AAA‐related death, 30 days4 compared with placebo (low certainty).
2 findings from 1 review
Nonfatal cardiovascular event, 30 days5 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in nonfatal cardiovascular event, 30 days5 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality, 6 months1 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in all‐cause mortality, 6 months1 compared with placebo (low certainty).
1 finding from 1 review
Non‐fatal cardiovascular events · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in nonfatal cardiovascular event, 6 months5 compared with placebo (low certainty).
1 finding from 1 review